Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Weller J, Schäfer N, Schaub C, Tzaridis T, Zeyen T, Schneider M, Potthoff AL, Giordano FA, Steinbach JP, Zeiner PS, Kowalski T, Sabel M, Hau P, Krex D, Grauer O, Goldbrunner R, Schnell O, Tabatabai G, Ringel F, Schmidt-Graf F, Brehmer S, Tonn JC, Bullinger L, Vajkoczy P, Glas M, Vatter H, Herrlinger U, Seidel C. Weller J, et al. Among authors: schaub c. J Neurooncol. 2023 Jan;161(1):147-153. doi: 10.1007/s11060-022-04203-4. Epub 2023 Jan 7. J Neurooncol. 2023. PMID: 36609807 Free PMC article. Clinical Trial.
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: schaub c. J Neurooncol. 2023 Nov;165(2):387. doi: 10.1007/s11060-023-04488-z. J Neurooncol. 2023. PMID: 37921974 Free PMC article. No abstract available.
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
Weller J, Zeyen T, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Hau P, Seidel C, Goldbrunner R, Tabatabai G, Vatter H, Tzaridis T, Schneider M, Herrlinger U. Weller J, et al. Among authors: schaub c. J Neurooncol. 2023 Sep;164(3):749-755. doi: 10.1007/s11060-023-04470-9. Epub 2023 Oct 3. J Neurooncol. 2023. PMID: 37787906 Free PMC article.
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: schaub c. J Neurooncol. 2023 Sep;164(3):607-616. doi: 10.1007/s11060-023-04444-x. Epub 2023 Sep 20. J Neurooncol. 2023. PMID: 37728779 Free PMC article.
176 results